about
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision.Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature.Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes.Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy."What if…": decisional regret in patients who discontinued active surveillance.Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy.Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma.Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience.A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.CT-guided percutaneous cryoablation of renal masses in selected patients.Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.Eleven-year management of prostate cancer patients on active surveillance: what have we learned?A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal.Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease.Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell TumorsPostchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial DesignRelationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastasesInterim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell CarcinomaFuncion Sparing Surgery in Uro-Oncology: Germ Cell Tumors of the TestisThe Treatment of Early-Stage Germ Cell Tumors of the Testis (GCTT)Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node DissectionRetroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence
P50
Q33383428-593E4CA9-DD60-4FA8-838C-8593E0C1806CQ33409143-16604C36-2234-4282-8B6C-CE72F18F7AE0Q33412487-3A29FA30-8E26-4A90-993C-D8021D5265F9Q36283587-0AD449CF-505F-4E19-B0F7-CFF4124BF191Q38173301-54CA1751-AC49-4367-939C-B1FAEF98C470Q38248583-BAB706EA-8F61-4274-8EEA-B42EF93C21C0Q38390250-7F4048F4-7444-4703-A584-2DA7988A733DQ39311814-0A49E015-437B-4473-A380-D924CAFC7C1BQ40815142-754FCDF2-37D6-4064-8812-DC737E6975A7Q40867911-EB96C102-7A0A-4A58-8300-A6E8AC3258D8Q40927886-FA3C694B-110A-4613-AEC9-4AACA1EF0423Q43773181-E647760B-2F5D-44F5-8383-4FDCDBA6B36FQ44025519-14097BFF-60E7-4F42-B947-B1FBC13A5B5DQ44928349-7A0C442E-75F6-44F2-9C4F-AE80131B9D46Q47586586-F2009A7C-7592-48D4-B27D-F85F4C61C3BBQ48220175-F77F03EC-DC1A-419F-AA68-745397454336Q48304341-B9454138-3E25-43E4-84B3-64E96A869CC2Q48632510-450F8872-7078-47A1-A46B-459D3417E922Q50859007-D947FDB0-0CA5-4A04-B41E-F1626A9EF899Q53167291-0E738C07-5AE5-41FB-86ED-28C106E9AABBQ53634902-A7F467C1-E05B-4F23-AD9A-7F1B743F93D8Q54416374-41B667D5-72A2-4978-956B-155BDF3D769DQ54693710-1BD25886-2B1B-4F9F-83E2-4119781E5DC6Q57575079-F1D37DFC-EA76-45AA-A81F-0A81025EFEE2Q57575092-824B7AE2-A705-438F-8D56-A30146A9C840Q57575095-E9249C43-6374-4074-8421-94A6DB01CB4FQ57575101-7799975B-C43F-4D14-B53A-604E72FE29D8Q57575102-28306878-2B6B-48EA-BEC2-A0D41CE24E1CQ57575107-DC1F21BC-E4CC-4821-A7C0-175B49247DF9Q57575108-0BCD6FDF-A467-471D-BBF9-C83278F86BB3Q57575114-5D4550EA-4D64-4AAC-B40C-9B573F9B2CB4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Stagni
@ast
Silvia Stagni
@en
Silvia Stagni
@es
Silvia Stagni
@nl
Silvia Stagni
@sl
type
label
Silvia Stagni
@ast
Silvia Stagni
@en
Silvia Stagni
@es
Silvia Stagni
@nl
Silvia Stagni
@sl
prefLabel
Silvia Stagni
@ast
Silvia Stagni
@en
Silvia Stagni
@es
Silvia Stagni
@nl
Silvia Stagni
@sl
P106
P1153
6701386313
P21
P31
P496
0000-0003-0089-4713